Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Targeted therapies in thyroid carcinoma.
| Therapeutic |
Target(s) (Inhibitory effects) |
Median progression free survival |
|---|---|---|
| Vemurafenib | BRAFV600E | 50% of patients with progression-free survival of ~18 months (33) |
| Dabrafenib | BRAFV600E | 50% of patients with progression-free survival of ~11.3 months (34) |
| Sorafenib | Multi-kinase (including BRAFWT and BRAFV600E) | ~17.9 months (35) |
| Lenvatinib | VEGFR1-3, FGFR1-4, PDGFRα, PDGFRβ, KIT, RET (36–38) | ~18.3 months (39) |
